3^rd World Congress on Advancements in Tuberculosis and Lung Diseases November 22-23, 2021 Singapore City, Singapore

Biography:

Dr. Rahul Hajare has been a hard worker all his academic life. After his Ph.D in Pharmacy from Bangalore which he completed with flying colours, he is fortunate to work NARI primer HIV research Institute to complete Post Doc of World Renowned Scientist Respected Dr. R.S.Paranjape., Retired Director & Scientist ‘G’ National AIDS Research Institute Pune. Dr. Rahul Hajare has Associate Professor of Medical Chemistry to Pune University (until 2020), Dr. Rahul Hajare now Principal of Ishwar Deshmukh Institute of Pharmacy affiliated to council f India

Abstract:

Other events has vagina experiencing pain, discomfort, lack of sensation, struggling to orgasm, and has overall displeased with the aesthetic outcome of labiaplasty long history of revisiting and repairing botched labiaplasty. Ideally, the revision required post-original labia reduction would be minimal, and may consider using for the touch-ups. But sometimes that has not the right decision and a new perspective and expertise has warranted.                                                                                                                            14.8 million Indian struggle with vaginal depression. 1 in 8 suffers with symptoms of depression. The Pandemic facing the world has adding even more to those numbers.  Depression affects how people think, feel and interact with others, face has walnut. Many sufferers have trouble doing day to day tasks and may think life has not worth living. Clinical depression has much more than a few days of feeling sad. Patients suffering with depression may feel an emptiness that cannot be filled, experience appetite changes, have thoughts of suicide, suffer with physical pain and can no longer find pleasure in activities that they once enjoyed. Family history, sleep disorders, traumatic events and medications can also cause and contribute to one's Depression. Researchers have found that changes in the brain occur during depression. Some patients exhibit changes in serotonin levels, dopamine levels and norepinephrine levels in the brain. These neurotransmitters send signals to the synaptic passages in the brain that controls emotions. Researcher has seen poverty during early service. Also, when working in the power politics institute in Pune University researcher observed that trustee take poor employees to bed hungry. Our entire team at Aguirre Specialty Care would like to assure you that have heightened all of precautionary standards and procedures to maximum levels to ensure the safety and well-being of our patients and staffs.

Biography:

Abstract:

Tuberculosis (TB) is an infectious disease which causes death after HIV, mostly in a tropical and developing country like Indonesia. TB infection can be categorized into tropical neglected disease epidemiologically as the patients are mostly from slum area, dense population, rural, and poor family who have many obstacles in healing process. TB is caused by an infectious bacteria, mycobacterium tuberculosis, which is contagious easily. Multi Drug Resistant (MDR-TB) is the biggest problem in preventing and curing TB in the world. Indonesia is in the 8^th of 27^th country which has big issue of TB. MDR-TB diagnosis recently uses GeneXpert. This tool spends a big cost and expensive to be bought therefore only a few hospitals can afford it. Furthermore, it needs training and skilled persons to use it in diagnosing MDR-TB. This research aims to solve the problem by creating a tissue design integrated-CRISPR/Cas9 System as MDR-TB sensor. This research uses literature review method. CRISPR or Cluster Regularly Interspaced Short Palindromic Repeats has been used mostly as genome editing. This concept uses CRISPR to detect specific resistant genes, rifampisin and isoniazid, in tuberculosis bacteria. If the patient has MDR-TB, the tissue will turn blue as it detects rifampisin and isoniazid.

Biography:

Dr. Amit Sharma has done his MBBS from  Maulana Azad Medical College and MD in Pulmonary Medicine from Vallabhbhai Patel Chest Institute both under University of Delhi. He is working in NITRD from 2010 as a Chest Physician and has almost 19 years of experience in managing Tuberculosis and Respitary Diseases. He has been a Supervisor and Co-supervisor in the dissertation of more than 10 PG Residents and is the first or second author in 4 international and 1 national publication.        
 

Abstract:

Bedaquiline (BDQ)  has emerged as new hope in the treatment of MDR TB especially in more complicated cases harboring additional drug resistance such as Fluroroquinolone  (FQ) resistance. Wiht its unique mechanism of action whereby it inhibits the Mycobacterial ATP synthase, It promises better success rate for a disease with an otherwise dismal prognosis. NITRD, a tertiary Centre for TB and respiratory diseases was one of the initial sites for implementation of BDQ containing regimens. In our study, we tried to assess the treatment outcome of 43 patients of NITRD which were started on BDQ based regime. Our results showed that more than one-third of the patients (69.8%) had favourable outcome as cure or treatment completed. Unfavourable outcome was mostly associated with increasing age, extensive involvement of Lung parenchyma, addictions (alcoholism, smoking) and concurret Diabetes. Culture conversion time, type of TB, whether Pulmonary or Extra-pulmonary, type of resistance, Second line injectables (SLI) and/or Fluoroquinolone (FQ) and Sputum smear grading were not found to have any association with the treatment outcome of patients on Bedaquiline containing regimen. Our results are encouraging since a good outcome was achieved in patients with more extensive resistace pattern. BDQ has emerged has a potent weapon in the arsenall of anti-tubercular drugs and is now classified in the group A drugs for treatment of MDR TB. Its use is now finding application in national as well as international TB Elimination programmes all around the globe.

Biography:

Pooja has completed her Bachelors’ from Bombay College of Pharmacy, India and her Masters’ at from Creighton University, Nebraska. She is currently pursuing her PhD at the University of Minnesota under the guidance of Dr. Courtney Aldrich. She is actively involved with a number of student groups and enjoys networking.

Abstract:

Tuberculosis (TB) is one of the deadliest infectious disease resulting in nearly 1.5 million deaths annually and infecting nearly one-quarter of the population. Para-aminosalicylic acid (PAS), an important second-line agent for treating drug-resistant mycobacteria, has low bioavailability and rapid clearance that necessitate high daily doses of up to 12 grams/day, which in turn causes severe gastrointestinal disturbances by disruption of gut microbiota and host epithelial cells.  In this project we aim to improve the bioavailability of PAS, while retaining its anti-mycobacterial activity. We have developed a series of prodrugs that substantially increase the oral bioavailability, which prevents intestinal accumulation as well as undesirable bioactivation by the gut microbiome to non-natural folate species that exhibit cytotoxicity. The conceptually simple prodrug approach does not address the intrinsic rapid clearance of PAS by N-acetyltransferase (NAT); thus, we have also designed analogues of the PAS scaffold to lower clearance of PAS enzymes by sterically blocking N-acetylation and electronic deactivation of the para-amino group. Combination of these dual approaches together may provide a next-generation PAS drug with substantially higher oral exposure to prevent adverse reactions and development of resistance.

Biography:

Dr.Poornimaa has completed her BDS at the age of 23 years from Tamilnadu Dr.MGR Medical University and postdiploma in Clinical Cosmetology from ILAMED,University of Griesfwald. She is the Consultant at various Dental and Skin Clinic.She is in the process of publishing her studies in reputed journals.

Abstract:

Tuberculosis (TB) has a long history. It was present before the beginning of recorded history and has left its mark on human creativity, music, art and literature; and has influenced the advance of biomedical sciences and healthcare. Its causative agent, Mycobacterium tuberculosis, may have killed more persons than any other microbial pathogen (Daniel 2006).  Tuberculosis likely has been present in humans since the dawn of humankind. Every day in India more than 20,000 people become infected with the tubercle bacillus, more than 5000 develop the disease, and more than 1000 die from TB. The conditions are still unfavourable in many states in India, where the socio-economic and living conditions are unfavourable for the eradication of many diseases including TB.In developed countries tuberculosis is relatively less familiar.TB is generally referred as urban disease In India, tuberculosis kills 14 times more people than all tropical diseases combined, 21 times more than malaria, and 400 times more than leprosy. Every year, another 20 lac people develop tuberculosis in India, nearly one million of them highly infectious sputum positive cases — two such cases developing every minute. India annually spends a whopping Rs13, 000 cores each year to treat tuberculosis. My study is based on the awareness about tuberculosis among the health care workers and general population. As many scholars had suggested, improvements in socio-economic conditions played an important role in improvements in health status in the past.

Biography:

Dr .Arcot Dheenadayalu Nageswari is a Post Graduate in Tuberculosis and Respiratory Diseases. She was trained by Central Govt. of India in TB

Control (1983) she has the prestigious Fellowship award of by WHO in TB control Training at Japan and Korea 1993. She has published 20 papers in I Indexed national and international journals. She has more than 25 years of Clinical Experience in Tuberculosis and Chest diseases.

Abstract:

Tuberculosis was declared as global emergency by WHO in 1993. DOTS Therapy recommended by WHO is highly effective in an active drug susceptible TB as long as patient completes the course. Adverse effect of anti TB drugs is one of the most common reasons for non-adherence eventually contributing to treatment failure, relapse or emergence of drug resistance. The standard treatment for newly diagnosed tuberculosis patients consists of an intensive phase for two months with 4drugs (HRZE), followed by continuation phase for four months with 2 drugs (HR). Rifampicin, which is very effective against mycobacterium tuberculosis, in both phase of treatment, has certain concerns, which included decreased bioavailability with chronic use and hepatotoxicity. To overcome these concerns a new boosted formulation of Rifampicin (Risorine) with bio-enhancer of piparine was developed. Piperine has been found to increase bioavailablity of several drugs including Amoxicillin, Cefotaxime, Theophylline and Propanolol. Risorine is a fixed combination contains Rifampicin 200mg+Isonazid300mg+Piperine 10mg. We conducted study in two centres to validate the therapeutic efficacy and tolerablity of Risorine formulation containing regimen with a conventional regimen. This was a randomized, prospective, parallel group study . All the patients were subjected to sputum examination, biochemical investigations followed by adverse drug event (ADE) monitoring. A Total of 63 patients completed the study. No significant difference was observed in baseline characteristics of patients between the study groups. At the end of the continuous phase, both the groups showed zero bacteria detection. However, in the intervention group, the rate of sputum conversion was much faster than the usual care group. The rate of increase in SGOT and SGPT was much higher in the usual care group (p<0.0001) than the interventional group (p<0.05). Urea and creatinine has also increased from pre-treatment to end visit. The number of patients reported ADEs was less in the intervention care group (22.22%) when compared to the usual care group (36.84%). Rifampicin 200 mg with piperine 10 mg FDC is compatible with the usual CAT-1 regimen.